Joseph Schwartz
Stock Analyst at Leerink Partners
(4.18)
# 398
Out of 5,182 analysts
155
Total ratings
37.86%
Success rate
21.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Outperform | $210 → $215 | $143.83 | +49.48% | 5 | Mar 24, 2026 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $6 → $1 | $0.37 | +167.67% | 8 | Feb 24, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $24.28 | +188.30% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.46 | +0.28% | 13 | Dec 29, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $54.01 | +196.24% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $12.78 | +9.55% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $1.56 | +28.21% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $53.98 | +11.15% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $16.14 | -0.87% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $17.54 | +242.08% | 3 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $115 | $53.24 | +116.00% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $38.51 | +128.51% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $20.42 | -26.54% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $19.08 | +4.82% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $8.08 | +48.51% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $26.01 | +7.65% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $40.82 | -2.01% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.28 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $8.22 | +45.99% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.31 | +2,509.26% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $68.59 | -30.02% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $27.29 | -34.04% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $74.12 | -54.13% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $225.12 | -27.59% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.59 | +1,975.47% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.25 | +407.32% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $31.23 | -3.94% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $102.62 | -70.77% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.63 | +636.20% | 2 | Sep 26, 2017 |
Insmed
Mar 24, 2026
Maintains: Outperform
Price Target: $210 → $215
Current: $143.83
Upside: +49.48%
Gossamer Bio
Feb 24, 2026
Downgrades: Market Perform
Price Target: $6 → $1
Current: $0.37
Upside: +167.67%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $24.28
Upside: +188.30%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.46
Upside: +0.28%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $54.01
Upside: +196.24%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $12.78
Upside: +9.55%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $1.56
Upside: +28.21%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $53.98
Upside: +11.15%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $16.14
Upside: -0.87%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $17.54
Upside: +242.08%
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $53.24
Upside: +116.00%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $38.51
Upside: +128.51%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $20.42
Upside: -26.54%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $19.08
Upside: +4.82%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $8.08
Upside: +48.51%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $26.01
Upside: +7.65%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $40.82
Upside: -2.01%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $4.28
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $8.22
Upside: +45.99%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.31
Upside: +2,509.26%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $68.59
Upside: -30.02%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $27.29
Upside: -34.04%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $74.12
Upside: -54.13%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $225.12
Upside: -27.59%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.59
Upside: +1,975.47%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.25
Upside: +407.32%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $31.23
Upside: -3.94%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $102.62
Upside: -70.77%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.63
Upside: +636.20%